Cohance Lifesciences Approves Employee Stock Option Plans, Allots 30,190 Shares under ESOP 2023
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) announced the approval of its nomination and remuneration committee regarding its employee stock option plans. The committee approved key details related to both the new Cohance Lifesciences Limited Employee Stock Option Plan, 2026 (ESOP 2026), and actions concerning the existing Suven Pharmaceuticals Limited Employee Stock Option Plan, 2023 (ESOP 2023).Key decisions made by the Nomination and Remuneration Committee on July 23, 2026, included granting options to eligible employees under both schemes. Up to 19,748,317 stock options were approved for grant under the ESOP...